Abstract
Background
We investigated prognostic factors for biochemical recurrence (BCR) after robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node (LN) dissection.
Methods
We included 173 patients who underwent RARP with extended pelvic LN dissection without neoadjuvant therapy at our hospital between October 2010 and April 2018. BCR was defined as prostate serum antigen (PSA) levels ≥ 0.2 ng/mL; BCR-free survival rates were determined using Kaplan–Meier analysis. We used Cox regression analysis to evaluate effects of PSA and pathologic variables on BCR.
Results
Median follow-up was 27.9 (range 6.1–86.9) months. Five-year BCR-free survival was 89.5%. In multivariate analysis, positive LNs (HR 7.117; 95% CI 2.826–17.925; P < 0.001) and Gleason score (GS) ≥ 8 (HR 2.612; 95% CI 1.051–6.489; P = 0.039) were significant predictors of BCR. Patients with 1 or 2 positive LNs (n = 10) had significantly higher BCR-free survival rates than patients with ≥ 3 positive LNs (n = 5). We, therefore, stratified the patients as low-risk (GS < 8 and no positive LNs), intermediate-risk: (either GS ≥ 8 or positive LNs) and high-risk (both GS ≥ 8 and positive LNs). Their 1-year BCR-free survival rates were low-risk: 94.6%, intermediate-risk: 88.5%, and high-risk: 33.3% (P < 0.05).
Conclusions
Patients with 1–2 positive LNs and GS < 8 have low risk for BCR; close observation without immediate adjuvant hormonal therapy can be considered for these patients.
Similar content being viewed by others
References
Novara G, Ficarra V, Mocellin S et al (2012) Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol 62:382–404
Srougi V, Bessa J Jr, Baghdadi M et al (2017) Surgical method influences specimen margins and biochemical recurrence during radical prostatectomy for high-risk prostate cancer: a systematic review and meta-analysis. World J Urol 35:1481–1488
Fujimura T, Fukuhara H, Taguchi S et al (2017) Robot-assisted radical prostatectomy significantly reduced biochemical recurrence compared to retro pubic radical prostatectomy. BMC Cancer 17:454
Thompson JE, Egger S, Bohm M et al (2014) Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. Eur Urol 65:521–531
Koo KC, Jung DC, Lee SH et al (2014) Feasibility of robot-assisted radical prostatectomy for very-high risk prostate cancer: surgical and oncological outcomes in men aged %3e/=70 years. Prostate Int 2:127–132
Boorjian SA, Thompson RH, Siddiqui S et al (2007) Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178:864–870 (discussion 70–71)
Masterson TA, Bianco FJ Jr, Vickers AJ et al (2006) The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 175:1320–1324 (discussion 4–5)
Briganti A, Blute ML, Eastham JH et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55:1251–1265
Gandaglia G, De Lorenzis E, Novara G et al (2017) Robot-assisted radical prostatectomy and extended pelvic lymph node dissection in patients with locally-advanced prostate cancer. Eur Urol 71:249–256
Fossati N, Willemse PM, Van den Broeck T et al (2017) The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 72:84–109
Preisser F, van den Bergh RCN, Gandaglia G et al (2020) Effect of extended pelvic lymph node dissection on oncologic outcomes in patients with D'Amico intermediate and high risk prostate cancer treated with radical prostatectomy: a multi-institutional study. J Urol 203:338–343
Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
Mottet N, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 71: 618–629
Kim DK, Koo KC, Abdel Raheem A et al (2016) Single positive lymph node prostate cancer can be treated surgically without recurrence. PLoS ONE 11:e0152391
Briganti A, Karnes JR, Da Pozzo LF et al (2009) Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55:261–270
Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA (2014) Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 65:20–25
Bader P, Burkhard FC, Markwalder R et al (2003) Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 169:849–854
Morizane S, Honda M, Fukasawa S et al (2018) Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan. Int J Clin Oncol 23:568–575
Mohler J, Bahnson RR, Boston B et al (2010) NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Cancer Netw 8:162–200
Ploussard G, Briganti A, de la Taille A et al (2014) Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol 65:7–16
Palapattu GS, Allaf ME, Trock BJ et al (2004) Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 172:1860–1864
Liesenfeld L, Kron M, Gschwend JE et al (2017) Prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy. J Urol 197:143–148
Badani KK, Reddy BN, Moskowitz EJ et al (2018) Lymph node yield during radical prostatectomy does not impact rate of biochemical recurrence in patients with seminal vesicle invasion and node-negative disease. Urol Oncol 36(310):e1–e6
Poelaert F, Joniau S, Roumeguere T et al (2019) Current management of pT3b prostate cancer after robot-assisted laparoscopic prostatectomy. Eur Urol Oncol 2:110–117
Tosco L, Laenen A, Briganti A et al (2018) The EMPaCT classifier: a validated tool to predict postoperative prostate cancer-related death using competing-risk analysis. Eur Urol Focus 4:369–375
Messing EM, Manola J, Yao J et al (2006) Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7:472–479
Seiler R, Studer UE, Tschan K et al (2014) Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. J Urol 191:1280–1285
Schumacher MC, Burkhard FC, Thalmann GN et al (2008) Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54:344–352
Abdollah F, Gandaglia G, Suardi N et al (2015) More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer. Eur Urol 67:212–219
Abdollah F, Sun M, Thuret R et al (2012) Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. Int J Urol 19:645–651
Mattei A, Fuechsel FG, Bhatta Dhar N et al (2008) The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 53:118–125
Wilczak W, Wittmer C, Clauditz T et al (2018) Marked prognostic impact of minimal lymphatic tumor spread in prostate cancer. Eur Urol 74:376–386
Acknowledgements
The authors thank the nursing, medical engineering and anesthesia staffs at Tottori University Hospital. We also thank Marla Brunker, from Edanz Group (https://www.edanzediting.com/ac), for editing a draft of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Morizane, S., Honda, M., Shimizu, R. et al. Small-volume lymph node involvement and biochemical recurrence after robot-assisted radical prostatectomy with extended lymph node dissection in prostate cancer. Int J Clin Oncol 25, 1398–1404 (2020). https://doi.org/10.1007/s10147-020-01682-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-020-01682-1